NCT05989958 - The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Acute on Chronic Hepatic FailureLiver FailureHepatitis

Interventions

COMBINATION_PRODUCT

HepaCure

HepaCure will be administered in extracorporal dialysis following the treatment of DPMAS and LPE.

DEVICE

DPMAS and LPE

Using DPMAS and LPE for extracorporeal dialysis treatment.

Trial Locations (1)

RECRUITING

Beijing You'an Hospital affiliated to Capital Medical University, Beijing